Octapharma AG - Our Commitment

Octapharma works closely with the following patient organisations:

Immunotherapy

• IPOPI - International Patient Organisation for Primary Immunodeficiencies

• DSAI - Deutsche Selbsthilfe Angeborene Immundefekte, Germany
• GBS/CIDP Foundation International
• JMF - Jeffrey Modell Foundation
• The Neuropathy Action Association, USA
• IDF - Immune Deficiency Foundation, USA
• IRIS - Immuno-déficience primitive, Recherche, Information, Soutien

Coagulation Therapy:

Scientific/Physician Groups:

• AIR - Alpha One Registry International
  
• CIS - Clinical Immunology Society

Industry Organisations

• PPTA - Plasma Protein Therapeutics Association
• AGP - Arbeitsgemeinschaft Plasmaderivate Herstellender Unternehmen

Octapharma’s commitment to patient care started right from the very beginning. We have a history of setting the benchmark for product and patient safety by introducing innovative development strategies which help improve patient quality of life.

We firmly believe that by engaging top researchers in our clinical studies, regularly contributing new clinical information and establishing solid relationships with patient centred organisations, we can greatly improve treatments for the benefit of all patients living with diseases in the areas of

• Coagulation disorders (haematology)

• Immune disorders (immunotherapy)

• Intensive care and emergency medicine

Octapharma was the first manufacturer to apply the solvent/detergent (S/D) process to the production of all its products. By continuous investments in, and enhancement of, existing products as well as ongoing projects to develop a world-class product portfolio, we take good care of our patients in over 80 countries around the world.